These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17265415)

  • 1. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
    Bhasin M; Rowan E; Edwards K; McKeith I
    Int J Geriatr Psychiatry; 2007 Sep; 22(9):890-5. PubMed ID: 17265415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
    Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
    Ballard CG; Chalmers KA; Todd C; McKeith IG; O'Brien JT; Wilcock G; Love S; Perry EK
    Neurology; 2007 May; 68(20):1726-9. PubMed ID: 17502555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.
    Bhanji NH; Gauthier S
    J Neuropsychiatry Clin Neurosci; 2005; 17(4):552-5. PubMed ID: 16387998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
    Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors for dementia with Lewy bodies.
    Wild R; Pettit T; Burns A
    Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.
    Mori E; Ikeda M; Kosaka K;
    Ann Neurol; 2012 Jul; 72(1):41-52. PubMed ID: 22829268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of dementia with Lewy bodies.
    Josif S; Graham K
    JAAPA; 2008 May; 21(5):22-6. PubMed ID: 18556885
    [No Abstract]   [Full Text] [Related]  

  • 15. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: results from a 12-week multicentre, randomised, double-blind, and placebo-controlled phase IV study.
    Mori E; Ikeda M; Iseki E; Katayama S; Nagahama Y; Ohdake M; Takase T
    Psychogeriatrics; 2024 May; 24(3):542-554. PubMed ID: 38439118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.
    Mori S; Mori E; Iseki E; Kosaka K
    Psychiatry Clin Neurosci; 2006 Apr; 60(2):190-5. PubMed ID: 16594943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.